Latent autoimmune diabetes in adults

What it is

Latent autoimmune diabetes in adults (LADA) is a slow-progressing autoimmune form of diabetes that accounts for an estimated 2–12% of all diabetes diagnoses and is misidentified as type 2 diabetes in up to 10% of adults initially labelled with that condition. Also called type 1.5 diabetes or slow-onset type 1 diabetes, LADA shares the immune-mediated beta cell destruction of classic type 1 diabetes but presents in adulthood — typically between ages 30 and 50 — with a gradual course that can mimic type 2 diabetes for months to years.

The distinction matters clinically. Oral glucose-lowering agents that work by stimulating residual insulin secretion are less effective as beta cell mass erodes, and insulin therapy becomes necessary sooner than it would in true type 2 diabetes. In Canada, Diabetes Canada recognizes LADA as a distinct subtype and notes that routine HbA1c or fasting glucose testing alone cannot differentiate it from type 2 diabetes — autoantibody testing is required.

Feature	Type 1 diabetes	LADA (type 1.5)	Type 2 diabetes
Onset age	Childhood / adolescence	Usually 30–50	Usually >40
Speed of beta cell loss	Rapid (weeks–months)	Slow (months–years)	Gradual / insulin resistance
Autoantibodies (GADA)	Positive	Positive (70–80%)	Negative
Body habitus at diagnosis	Lean	Often lean/normal	Often overweight
Insulin required	Immediately	Eventually (all cases)	Often delayed or avoidable
C-peptide	Low/absent	Declining	Normal or elevated

Causes and mechanism

LADA is driven by an autoimmune attack on pancreatic beta cells. The immune system generates autoantibodies — most commonly glutamic acid decarboxylase antibodies (GADA), but also islet cell antibodies (ICA), insulin autoantibodies (IAA), and IA-2 antibodies — that progressively destroy insulin-producing tissue. GADA are positive in roughly 70–80% of LADA cases, making them the most sensitive single marker.

The underlying susceptibility is genetic: LADA shares HLA class II gene associations (particularly HLA-DR3 and HLA-DR4 haplotypes) with classic type 1 diabetes. Environmental triggers — viral infections and other immune stressors — are thought to initiate the autoimmune cascade in genetically predisposed individuals. Because the attack unfolds slowly, enough beta cell function persists at diagnosis to allow a period of oral medication management, which is why the condition so often goes unrecognized.

People with LADA are more likely to have co-existing autoimmune conditions — Hashimoto's thyroiditis, coeliac disease, and Addison's disease appear at higher rates than in the general population — reflecting a shared autoimmune predisposition.

Symptoms and diagnosis

Early LADA symptoms are indistinguishable from type 2 diabetes: increased thirst, frequent urination, fatigue, and blurred vision. Unexplained weight loss is somewhat more common in LADA than in typical type 2 presentations, but it is not universal.

Several clinical features should prompt a clinician to test for autoantibodies rather than assume type 2 diabetes:

• Adult onset without significant overweight or obesity
• Rapid deterioration of glycaemic control on oral medications
• Personal or family history of autoimmune conditions
• Insulin requirement developing much sooner than expected for type 2 diabetes

Diagnostic workup:

1. GADA testing — the first-line autoantibody test; positive in 70–80% of LADA cases. Available through LifeLabs and Dynacare in most Canadian provinces, though ordering practices vary by province and specialist access.
2. Additional autoantibodies (IA-2, ZnT8, ICA) — increase sensitivity when GADA is borderline or negative.
3. C-peptide — a low or declining fasting C-peptide confirms significant beta cell loss and supports the LADA diagnosis over type 2.
4. Standard diabetes testing — fasting glucose, HbA1c, and oral glucose tolerance test establish the diabetes diagnosis but cannot differentiate subtypes.

Treatment options

LADA management diverges from type 2 diabetes primarily in the timing and centrality of insulin therapy.

Insulin: Because beta cell destruction is progressive and inevitable, insulin replacement is the cornerstone of long-term LADA management. Starting basal insulin earlier — rather than escalating oral agents that depend on residual secretion — may preserve remaining beta cell function for longer. Most patients begin with a long-acting (basal) insulin and transition to a full basal-bolus regimen as beta cell capacity declines.

Oral agents: Metformin is reasonable in early LADA, particularly when insulin resistance coexists. DPP-4 inhibitors and GLP-1 receptor agonists have shown some signal toward beta cell preservation in small studies, though evidence remains limited. Sulfonylureas are generally avoided: they force already-stressed beta cells to work harder and may accelerate their destruction.

Monitoring: Regular HbA1c measurement, continuous or frequent blood glucose monitoring, and the same cardiovascular risk management applied to other diabetes types all apply. Screening for associated autoimmune conditions — thyroid antibodies, coeliac serology — is appropriate given the shared immune predisposition.

Canadian access note: Insulin and most oral diabetes medications are covered under provincial drug benefit programs (e.g., Ontario Drug Benefit, BC PharmaCare, Alberta Blue Cross) for eligible patients. Coverage criteria for newer agents like GLP-1 receptor agonists vary by province and indication; patients should confirm with their pharmacist or prescriber.

When to see a clinician in Canada

Request autoantibody testing from your family physician or endocrinologist if you carry a type 2 diabetes diagnosis and any of the following apply: you are lean or normal weight and the diagnosis never felt like a typical fit; your blood sugar is worsening quickly despite oral medications; you have another autoimmune condition or a first-degree relative with type 1 diabetes or an autoimmune disease; or you needed insulin far sooner than your clinician expected.

A single GADA blood test — orderable through LifeLabs or Dynacare with a requisition — can usually confirm or rule out LADA. Getting the right diagnosis earlier allows appropriate treatment selection and avoids the glycaemic instability that comes from managing autoimmune diabetes with oral agents alone.

Limitations and open questions

Research is still emerging on several aspects of LADA. There is no universally agreed diagnostic threshold for GADA positivity, and some classification systems require additional criteria (age, absence of insulin requirement for at least six months post-diagnosis) that are not applied consistently across centres. Whether LADA is truly a distinct disease entity or simply adult-onset type 1 diabetes on a slower trajectory remains debated in the literature.

Evidence for the beta cell-preserving effects of DPP-4 inhibitors and GLP-1 receptor agonists in LADA is preliminary — most supporting data come from small, short-duration trials, and no large randomized controlled trial has established a standard of care specific to LADA. Health Canada has not issued LADA-specific prescribing guidance; management is extrapolated from type 1 and type 2 diabetes frameworks. The optimal timing for insulin initiation — and whether early insulin meaningfully slows autoimmune progression — also remains an open question in ongoing trials.